ELQ-300
| Names | |
|---|---|
| Preferred IUPAC name
6-Chloro-7-methoxy-2-methyl-3-{4-[4-(trifluoromethoxy)phenoxy]phenyl}quinolin-4(1H)-one | |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C24H17ClF3NO4 | |
| Molar mass | 475.85 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
ELQ-300 is an experimental antimalarial medication. It is the first entry in a new class of antimalarials known as 4-quinolone-3-diarylethers.[1]
ELQ-300 acts as an inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain) - A mechanism shared with some of the most potent fungicides known, the strobilurins.[1] In preclinical studies with mice, ELQ-300 was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability.[1]
Due to issues with crystallization, ELQ-300 was turned into a prodrug known as ELQ-331. ELQ-331 and two other similar drug candidates are currently in development.[2]
References
- ^ a b c Nilsen A; et al. (2013). "Quinolone-3-diarylethers: a new class of antimalarial drug". Science Translational Medicine. 5 (177): 177ra37. doi:10.1126/scitranslmed.3005029. ISSN 1946-6234. PMC 4227885. PMID 23515079.
- ^ pubs.acs.org. doi:10.1021/acsinfecdis.4c00140?ref=article_openPDF https://pubs.acs.org/action/cookieAbsent. Retrieved 2026-03-16.
{{cite web}}: Missing or empty|title=(help)
Further reading
- "NIH-Supported Researchers Identify New Class of Malaria Compounds" (Press release). U.S. National Institutes of Health. March 20, 2013. Archived from the original on March 24, 2013.